PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Highlights Beta-Amyloid 1-42 Peptides - AnaSpec, EGT Group is one of the world's most trusted sources of integrated proteomic solutions specifically designed for Alzheimer's Disease research - AnaSpec.com
AnaSpec Highlights Beta-Amyloid 1-42 Peptides

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/06/27 - AnaSpec, EGT Group is one of the world's most trusted sources of integrated proteomic solutions specifically designed for Alzheimer's Disease research - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Our large collection of ß-Amyloid (1-42) peptides includes:

Native sequences – human and mouse/rat sequences (unless otherwise specified, sequences are human in origin)
Single or multiple amino acid substitution sequences, e.g. S26C
Biotin labeled sequences – N or C terminally labeled, with or without linker
Dye labeled sequences – HiLyte Fluor™ or classic dye labeled
ClearPoint™ heavy-isotope labeled sequences
Shorter sequences that end on the 42nd amino acid and analog
HFIP treated β-Amyloid (1-42)
ß-Amyloid (Aß) peptides are generated as cleavage products 39 to 43 amino acids in length from the membrane protein, Amyloid Precursor Protein (APP) by two proteases, β-secretase and γ-secretase.1-3 While only a small amount is processed by β-Secretase, also known as BACE1 (β-secretase APP cleaving enzyme) or memapsin, APP is predominantly processed by α-Secretase, producing a 83-amino acid C-terminal fragment, C83. Subsequent cleavage of C83 by γ-secretase produces a non-toxic N-terminal 3kD protein.1-2
Aßs are amphiphilic peptides with a hydrophilic N-terminal domain (residues 1 to 28) and a hydrophobic C-terminal (residues 29 to 40-42), the latter corresponding to a part of the transmembrane domain of APP.4 β-Amyloid assembly into fibrils is initiated by a conformational transition from random coil to β-sheet (hence the name β-amyloid) and a nucleation-dependent aggregation process.4 Aβ peptides that are 39 to 42 amino acid residues in length with a molecular mass of approximately 4 kDa are the core components of neuritic plaques seen in Alzheimer’s disease (AD) brains. The presence of excess amount of Aß deposits and neurofibrillary tangles, NFTs, 5-6 comprising of hyperphosphorylated Tau proteins are the hallmarks of an AD brain.1
Aβ (1-42), a major component of amyloid plaques, accumulates in neurons of Alzheimer’s disease (AD) brains. Biochemical analysis of the amyloid peptides isolated from AD brain indicates that Aβ (1-42) is the principal species associated with senile plaque amyloids, while Aβ (1-40) is more abundant in cerebrovascular amyloid deposit.7-8

References:

1. Selkoe DJ. Nature 399, A23 (1999).
2. Suh, Y-H. and F. Checler, Pharmacol Rev 54, 469 (2002).
3. Kang, J. et al. Nature 325, 733 (1987).
4. Jarrett, JT. et al. Biochem 32, 4693 (1993).
5. Masters, CL. et al. EMBO J 4, 2757 (1985).
6. Braak, H. et al. Acta Neuropathol 87, 554 (1994).
7. Nagele, R. et al. Neurosci 110, 199 (2002).
8. Garzon-Rodriguez, W. et al. J Biol Chem 272, 21037 (1997).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Highlights Beta-Amyloid 1-42 Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  1Click Games





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)